Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Neoplasms × Calcium Dobesilate × Clear all

Phase

Phase 2 5 Phase NA 3 Phase 4 2 Phase 1 2 Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Multiple Myeloma 32 Recurrence 10 Precursor Cell Lymphoblastic Leukemia-Lymphoma 8 Neoplasms, Plasma Cell 6 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3 Lymphoma, Non-Hodgkin 3 Lymphoma, Mantle-Cell 3 Lymphoma 3 Lymphoma, Large B-Cell, Diffuse 2 Lung Neoplasms 2 Immunoglobulin Light-chain Amyloidosis 2 Carcinoma, Non-Small-Cell Lung 2 Burkitt Lymphoma 2 Amyloidosis 2 Waldenstrom Macroglobulinemia 1 Uterine Cervical Neoplasms 1 Smoldering Multiple Myeloma 1 Rectal Neoplasms 1 Proteostasis Deficiencies 1 Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphodepleting Chemotherapy 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Acute 1 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1

Interventions

pembrolizumab 37 Nivolumab 24 Gemcitabine 24 Paclitaxel 16 Carboplatin 14 Cyclophosphamide 12 Cisplatin 12 Ipilimumab 10 Capecitabine 10 Irinotecan 8 Docetaxel 8 Dexamethasone 8 Bevacizumab 8 130-nm albumin-bound paclitaxel 8 Rituximab 7 Albumin-Bound Paclitaxel 7 Temozolomide 6 Sorafenib 6 Pemetrexed 6 Cetuximab 6 Azacitidine 6 Ascorbic Acid 6 spartalizumab 5 lenvatinib 5 fludarabine 5 cemiplimab 5 Radiotherapy 5 ibrutinib 4 avelumab 4 atezolizumab 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡